olivLaw · US equity research
Viatris Inc. VTRS
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
Viatris (VTRS) is a US-based global healthcare company supplying generic, branded and innovative medicines to patients in more than 165 countries. Revenues were 7.27 billion USD in the first half of 2026 and 3.8 billion USD in the second quarter, with a U.S. GAAP net loss of 119 million USD driven mainly by a non-cash write-down tied to the Tyrvaya sale. The company raised its 2026 guidance midpoints but also announced a restructuring program with workforce reduction of up to about 10%.
At the close of 02 Nov 2026, Viatris Inc. (VTRS) stock was 18.67 USD (−1.94% on the day), with market capitalisation 21.4 bn USD, dividend yield 2.57%, beta 0.78, 52-week range 10.11–19.20 USD. Latest reported quarter (Q2 2026): revenue of 3.8 bn USD (+4.9% YoY), diluted EPS -0.10 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 57.8
- strong (55–70)
- Bollinger (20, 2)
- 17.02 – 19.36
- in the upper half of the band · %B 0.71 · band width 12.9%
- SMA 50 / 200
- 17.50 / 15.92
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.40 / 0.36
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +6.1% | −2.3% | +8.4 pp | — |
| 3 months | +5.9% | −0.8% | +6.7 pp | — |
| 6 months | +22.8% | +4.7% | +18.1 pp | — |
| Year to date | +50.0% | +10.2% | +39.8 pp | — |
| 1 year | +80.2% | +10.3% | +70.0 pp | +25.4% |
| 3 years | +101.4% | +73.0% | +28.4 pp | +100.8% |
| 5 years | +34.3% | +61.8% | −27.5 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.8 bn | 3.5 bn | 3.3 bn | 3.6 bn | 3.8 bn | 3.7 bn | 3.5 bn | 3.8 bn |
| Cost of revenue | 2.3 bn | 2.3 bn | 2.1 bn | 2.2 bn | 2.4 bn | 2.6 bn | 2.4 bn | 2.3 bn |
| Gross profit | 1.5 bn | 1.2 bn | 1.2 bn | 1.3 bn | 1.4 bn | 1.1 bn | 1.2 bn | 1.5 bn |
| Research & development | 198.4 m | — | 222.0 m | 218.8 m | 250.4 m | — | 248.6 m | 248.3 m |
| SG&A | 1.0 bn | 1.0 bn | 948.1 m | 928.7 m | 886.6 m | 1.0 bn | 928.8 m | 1.1 bn |
| Operating income | 225.9 m | -179.8 m | -2.9 bn | 233.0 m | 178.8 m | -192.7 m | -79.7 m | 6.3 m |
| Depreciation & amortisation | 669.7 m ≈ | 746.2 m | 664.7 m | 678.3 m ≈ | 688.5 m ≈ | 766.8 m | 676.1 m | 672.3 m ≈ |
| Interest expense | 145.6 m | 120.2 m | 115.5 m | 116.6 m | 119.6 m | 119.6 m | 120.1 m | 120.7 m |
| Pre-tax income | 90.5 m | -526.5 m | -3.1 bn | -217.1 m | -7.9 m | -343.0 m | -247.3 m | -64.0 m |
| Income tax | -4.3 m | -10.0 m | -55.0 m | -212.5 m | 120.3 m | -2.9 m | -423.7 m | 54.8 m |
| Diluted EPS | 0.08 | — | -2.55 | 0.00 | -0.11 | — | 0.15 | -0.10 |
| Operating cash flow | 826.5 m ≈ | 482.7 m | 535.5 m | 219.7 m ≈ | 744.9 m ≈ | 815.8 m | 388.3 m | 381.8 m ≈ |
| Capex | 77.0 m ≈ | 140.4 m | 42.6 m | 52.9 m ≈ | 86.8 m ≈ | 196.5 m | 39.9 m | 52.8 m ≈ |
| Share repurchases | 0 ≈ | 0 | 175.4 m | 175.0 m | 67.9 m | 85.1 m | 0 | 150.0 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 11.4 bn | 11.5 bn | 11.9 bn | 17.9 bn | 16.3 bn | 15.4 bn | 14.7 bn | 14.3 bn |
| Revenue YoY | unavailable | +0.6% | +3.9% | +49.7% | −9.1% | −5.1% | −4.5% | −3.0% |
| Net income | 352.5 m | 16.8 m | -669.9 m | -1.3 bn | 2.1 bn | 54.7 m | -634.2 m | -3.5 bn |
| Net income YoY | unavailable | −95.2% | −4,087.5% | unavailable | unavailable | −97.4% | −1,259.4% | unavailable |
| Diluted EPS | 0.68 | 0.03 | -1.11 | -1.05 | 1.71 | 0.05 | -0.53 | -3.00 |
| Diluted EPS YoY | unavailable | −95.6% | −3,800.0% | unavailable | unavailable | −97.1% | −1,160.0% | unavailable |
| net % | 3.1% | 0.1% | -5.6% | -7.1% | 12.8% | 0.4% | -4.3% | -24.6% |
| Free cash flow | 2.1 bn | 1.6 bn | 988.8 m | 2.6 bn | 2.6 bn | 2.5 bn | 2.0 bn | 1.9 bn |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 1.3 bn USD
- Financial debt
- 14.4 bn USD
- Net debt
- 13.1 bn USD
- Equity
- 14.7 bn USD
- Total assets
- 37.2 bn USD
- Debt / equity
- 0.98x
- Current ratio
- 1.38x
- ROE
- -21.1%
- ROA
- -8.9%
- FCF margin
- 13.5%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 11.9 bn | 17.9 bn | 16.3 bn | 15.4 bn | 14.7 bn | 14.3 bn | SEC (XBRL)· 26 Feb 2026verified |
| Cost of revenue | 8.1 bn | 12.3 bn | 9.8 bn | 9.0 bn | 9.1 bn | 9.3 bn | SEC (XBRL)· 26 Feb 2026verified |
| Gross profit | 3.8 bn | 5.6 bn | 6.5 bn | 6.4 bn | 5.6 bn | 5.0 bn | SEC (XBRL)· 26 Feb 2026verified |
| Research & development | 555.1 m | 751.1 m | — | — | — | — | SEC (XBRL)· 28 Feb 2022verified |
| SG&A | 3.3 bn | 4.5 bn | 4.2 bn | 4.1 bn | 4.1 bn | 3.8 bn | SEC (XBRL)· 26 Feb 2026verified |
| Operating income | -210.8 m | -34.0 m | 1.6 bn | 766.2 m | 10.1 m | -2.7 bn | SEC (XBRL)· 26 Feb 2026verified |
| Depreciation & amortisation | 2.2 bn | 4.5 bn | 3.0 bn | 2.7 bn | 2.9 bn | 2.8 bn | SEC (XBRL)· 26 Feb 2026verified |
| EBITDA | 2.0 bn ≈ | 4.5 bn ≈ | 4.6 bn ≈ | 3.5 bn ≈ | 2.9 bn ≈ | 135.2 m ≈ | SEC (XBRL)· 26 Feb 2026derived |
| Interest expense | 497.8 m | 636.2 m | 592.4 m | 573.1 m | 550.0 m | 471.3 m | SEC (XBRL)· 26 Feb 2026verified |
| Pre-tax income | -721.2 m | -664.4 m | 2.8 bn | 202.9 m | -623.2 m | -3.7 bn | SEC (XBRL)· 26 Feb 2026verified |
| Income tax | -51.3 m | 604.7 m | 734.6 m | 148.2 m | 11.0 m | -150.1 m | SEC (XBRL)· 26 Feb 2026verified |
| Net income | -669.9 m | -1.3 bn | 2.1 bn | 54.7 m | -634.2 m | -3.5 bn | SEC (XBRL)· 26 Feb 2026verified |
| Diluted EPS | -1.11 | -1.05 | 1.71 | 0.05 | -0.53 | -3.00 | SEC (XBRL)· 26 Feb 2026verified |
| Weighted average diluted shares | 601.2 m | 1.2 bn | 1.2 bn | 1.2 bn | — | — | SEC (XBRL)· 26 Feb 2026verified |
| Dividend per share | — | 0.33 | 0.48 | 0.48 | 0.48 | 0.48 | SEC (XBRL)· 26 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 844.4 m | 701.2 m | 1.3 bn | 991.9 m | 734.8 m | 1.3 bn | SEC (XBRL)· 26 Feb 2026verified |
| Receivables | 4.8 bn | 4.3 bn | 3.8 bn | 3.7 bn | 3.2 bn | 3.0 bn | SEC (XBRL)· 26 Feb 2026verified |
| Inventories | 5.5 bn | 4.0 bn | 3.5 bn | 3.5 bn | 3.9 bn | 4.0 bn | SEC (XBRL)· 26 Feb 2026verified |
| Current assets | 12.9 bn | 10.9 bn | 10.6 bn | 13.0 bn | 9.5 bn | 9.8 bn | SEC (XBRL)· 26 Feb 2026verified |
| Property, plant & equipment, net | 3.5 bn | 3.2 bn | 3.0 bn | 2.8 bn | 2.7 bn | 2.6 bn | SEC (XBRL)· 26 Feb 2026verified |
| Goodwill | 12.3 bn | 12.1 bn | 10.4 bn | 9.9 bn | 9.1 bn | 6.8 bn | SEC (XBRL)· 26 Feb 2026verified |
| Intangibles (excl. goodwill) | 29.7 bn | 26.1 bn | 22.6 bn | 19.2 bn | 17.1 bn | 15.1 bn | SEC (XBRL)· 26 Feb 2026verified |
| Total assets | 61.6 bn | 54.8 bn | 50.0 bn | 47.7 bn | 41.5 bn | 37.2 bn | SEC (XBRL)· 26 Feb 2026verified |
| Short-term debt | 2.3 bn | 1.9 bn | 1.3 bn | 1.9 bn | 600.0 k | 1.9 bn | SEC (XBRL)· 26 Feb 2026verified |
| Long-term debt | 22.4 bn | 19.7 bn | 18.0 bn | 16.2 bn | 14.0 bn | 12.5 bn | SEC (XBRL)· 26 Feb 2026verified |
| Current liabilities | 10.6 bn | 9.9 bn | 6.7 bn | 7.8 bn | 5.8 bn | 7.1 bn | SEC (XBRL)· 26 Feb 2026verified |
| Total liabilities | 38.6 bn | 34.4 bn | 28.9 bn | 27.2 bn | 22.9 bn | 22.5 bn | SEC (XBRL)· 26 Feb 2026verified |
| Equity | 23.0 bn | 20.5 bn | 21.1 bn | 20.5 bn | 18.6 bn | 14.7 bn | SEC (XBRL)· 26 Feb 2026verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.2 bn | 3.0 bn | 3.0 bn | 2.9 bn | 2.3 bn | 2.3 bn | SEC (XBRL)· 26 Feb 2026verified |
| Capex | 243.0 m | 457.2 m | 406.0 m | 377.0 m | 326.0 m | 378.8 m | SEC (XBRL)· 26 Feb 2026verified |
| Free cash flow | 988.8 m ≈ | 2.6 bn ≈ | 2.6 bn ≈ | 2.5 bn ≈ | 2.0 bn ≈ | 1.9 bn ≈ | SEC (XBRL)· 26 Feb 2026derived |
| Investing cash flow | -301.1 m | -117.8 m | 1.5 bn | -864.5 m | 1.8 bn | -427.7 m | SEC (XBRL)· 26 Feb 2026verified |
| Financing cash flow | -605.7 m | -3.0 bn | -3.9 bn | -2.3 bn | -4.3 bn | -1.3 bn | SEC (XBRL)· 26 Feb 2026verified |
| Share repurchases | 0 | 0 | 0 | 250.0 m | 250.0 m | 500.5 m | SEC (XBRL)· 26 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 23 / 100
A scoring methodology on indicators and valuation, not investment advice.
score < 40
Closing price
02 Nov 2026Source: olivLaw, closing series
Market cap: 21.4 bn USD
Key indicators
Coverage and freshness
Score by group
- Quality8
- Growth0
- Valuation57
- Balance sheet13
- Returns20
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 6.31 – 37.13 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)16.58 – 37.13 (Mid 23.88)WACC 7.7% · starting FCFF 2.4 bn USD · terminal value share of EV 78%The WACC × g sensitivity gives the method's bounds; these are not probabilities.Reverse DCF: starting growth implied by the price (fading linearly to terminal growth, everything else fixed): -10.7%
- Peers: EV/EBITDAunavailable · not enough peers
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)6.31 – 8.48 (Mid 7.24)
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Unattractive profile · Score 23/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | -0.3% | 0 (on a fixed band) | 15% |
| Net margin · Quality | -23.9% | 20 (vs peers) | 9% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -4.2% | 0 (on a fixed band) | 12% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | 4.6x | 0 (on a fixed band) | 15% |
| Interest coverage · Balance sheet | -0.2x | 0 (on a fixed band) | 9% |
| Current ratio · Balance sheet | 1.6x | 65 (on a fixed band) | 6% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | 12.5x | 23 (on a fixed band) | 15% |
| FCF yield · Valuation | 9.1% | 100 (on a fixed band) | 12% |
| Shareholder yield (distributions) · Returns | 1.4% | 20 (on a fixed band) | 9% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet13/100 · 3/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality8/100 · 2/3 factors with a value
- Returns· partial20/100 · 1/2 factors with a value
- Valuation57/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
VIATRIS INC. (VTRS). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 14.3 bn USD in 2025; YoY growth -3.0%; net margin -23.9%; ROE -23.6%; net debt/EBITDA 4.6x.
The estimated value range is 11.44–22.81 USD per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 15.56 USD, the price of 18.67 USD leaves a potential of -16.7% (value / price − 1) and a margin of safety of -20.0% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 23/100, methodological classification: unattractive profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: growth, returns. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- FCF yield: 9.1%
What contradicts it
- ROIC: -0.3%
- Net margin: -23.9%
- Revenue CAGR 3Y: -4.2%
- Net debt / EBITDA: 4.6x
- Interest coverage: -0.2x
- EV/EBITDA: 12.5x
- Shareholder yield (distributions): 1.4%
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): FCF conversion, EPS CAGR 3Y, P/E (TTM), Payout ratio (FCF).
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 10 companies
Only companies with a capitalisation between 2.7 bn and 169.8 bn (within 8× of the company's); 365 of the vertical were left out.
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| VRTXVertex Pharmaceuticals Inc | 140.2 bn | 32.2 | 23.5% | 35.0% | +8.9% | +28% / +56% |
| BMYBristol-Myers Squibb Company | 128.8 bn | 14.0 | 44.1% | 18.5% | −0.2% | +28% / +28% |
| TEVATeva Pharmaceutical Industries Limited | 47.4 bn | 67.9 | 9.7% | 5.0% | +4.3% | +51% / +314% |
| ZTSZoetis Inc. | 34.4 bn | 13.7 | 64.4% | 27.5% | +2.3% | −35% / −53% |
| ROIVRoivant Sciences Ltd. | 25.9 bn | — | -6.2% | -3,535.0% | −71.6% | +72% / +275% |
| RPRXRoyalty Pharma plc | 25.8 bn | 37.7 | 8.5% | 32.1% | +5.1% | +66% / +146% |
| UTHRUnited Therapeutics Corporation | 25.6 bn | 21.3 | 19.3% | 41.6% | +10.6% | +23% / +148% |
| INSMInsmed Inc | 24.0 bn | — | -72.5% | -39.9% | +66.7% | −47% / +337% |
| VTRSViatris Inc. | 21.4 bn | — | -23.6% | -23.9% | −3.0% | +80% / +101% |
| ALNYAlnylam Pharmaceuticals, Inc. | 21.2 bn | 8.0 | 126.6% | 52.8% | +65.2% | −65% / −6% |
| REGNRegeneron Pharmaceuticals, Inc. | — | 21.2 | 14.9% | 28.5% | +1.0% | +23% / +17% |
1- and 3-year price returns: for VTRS from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Viatris (VTRS) is a US-based global healthcare company supplying generic, branded and innovative medicines to patients in more than 165 countries. Revenues were 7.27 billion USD in the first half of 2026 and 3.8 billion USD in the second quarter, with a U.S. GAAP net loss of 119 million USD driven mainly by a non-cash write-down tied to the Tyrvaya sale 3. The company raised its 2026 guidance midpoints but also announced a restructuring program with workforce reduction of up to about 10% 13.
SWOT
Strengths
- The company has a broad global footprint with a diversified portfolio of generics, complex products and established brands, supported by a large supply infrastructure 1.
- Sales growth in Greater China and Developed Markets shows the base business can return to positive momentum 3.
- Viatris has reduced its leverage and returned capital to shareholders, giving it more financial flexibility 3.
Weaknesses
- The company reported a GAAP net loss in the second quarter of 2026, driven by impairment-related charges on an asset sale, showing sensitivity of reported results to non-recurring items 3.
- Reliance on a limited number of manufacturing sites and third-party suppliers exposes the company to disruption, particularly in India where regulatory issues have arisen 12.
- Much of revenue comes from generics, which face strong price pressure and ongoing competition 1.
Opportunities
- Innovative products and launches in complex portfolios could open new revenue sources, especially if launched first to market 1.
- The restructuring programme could generate significant savings and free resources for growth investment 1.
- Partnerships and distribution agreements, such as those for biosimilars and Quvivq, could extend access to new markets 3.
Threats
- Price pressure from tender systems and government regulation could reduce sales and margins in many countries 1.
- Patent litigation and competitor strategies could delay launches or reduce generic revenue 1.
- Currency fluctuations and economic uncertainty could affect international results and the ability to pay dividends 1.
Risks
- Restructuring executionhigh
The restructuring programme might not achieve the expected savings or could cost more than announced, affecting cash flow and results 1.
- Manufacturing disruptionshigh
Problems at an Indian plant, combined with regulatory observations, could interrupt supply and reduce revenue in the second half of the year 23.
- Pricing pressuremedium
Government-imposed price cuts and tender systems could erode generic revenue, particularly in Developed Markets and Emerging Markets 1.
- Indebtednessmedium
The company carries significant debt, and refinancing could occur at higher interest rates, potentially limiting financial flexibility 1.
- Litigation and IT dependencelow
The company is involved in legal proceedings and relies on IT systems, exposing it to cybersecurity risks and adverse litigation outcomes 1.
Investment thesis
What would need to be true (bull case)
- Strong growth in Greater China and recent product launches could support a revenue recovery, and the raised 2026 guidance suggests confidence in execution 3.
- If the restructuring delivers the announced savings, operating margins could rise and free cash could fund investment and shareholder returns 1.
- A diversified portfolio across more than 165 countries provides a stable base, and lower leverage improves financial flexibility 13.
What would break the thesis
- Production disruptions in India and remediation risks could reduce second-half revenue and weigh on investor confidence 23.
- Pricing pressure and generic competition could limit margin improvement, especially if new launches are delayed 1.
- GAAP losses and restructuring costs could keep affecting reported results even as adjusted metrics improve 13.
What to watch
- Third-quarter results and the evolution of production disruptions at the Nashik facilityQ3 2026
- Progress of the restructuring programme and realisation of the announced savings2026
- US approval and launch of fast-acting meloxicam against its December 2026 PDUFA dateQ4 2026
- New product revenue versus the 450 to 550 million USD guidance2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Viatris defines its mission around access to quality medicines, supplying about 1 billion patients a year from more than 165 countries and territories with over 30,000 employees and 27 manufacturing, packaging and distribution sites 1. The portfolio combines generics, including complex products, established brands and a growing set of innovative medicines, and 2025 total revenues were 14.30 billion USD despite divestitures and the Indore impact 1. The strategy rests on three priorities: driving the base business, fuelling the innovative portfolio and modernising technology and data capabilities 1.
The company reshaped itself through successive divestitures, including women's healthcare in March 2024, the India API business in June 2024 and the OTC business in July 2024, along with contributing its biosimilars portfolio to Biocon Biologics 1. In October 2025 it acquired Aculys Pharma, gaining exclusive Japanese rights to pitolisant and Spydia Nasal Spray 1. In 2026 it has also begun selling non-core assets, such as the global rights to Tyrvaya and its stake in Biocon Limited 3.
Beyond marketed products, Viatris develops innovative candidates including selatogrel, cenerimod and fast-acting meloxicam, and the FDA approved the Gwyn Lo contraceptive patch in July 2026 13. The company still faces operational challenges, including remediation at an Indian plant where supply disruptions have occurred 23. How these efforts translate into durable growth remains to be seen.
Segments
Developed Markets
Developed Markets, mainly North America and Europe, generated net sales of 2193.7 million USD in the second quarter of 2026, up 4% reported and 2% operationally, supported by new product sales 3. This segment is the largest source of revenue, and its trajectory depends on launches and pricing pressure in the US and Europe 13.
Emerging Markets and JANZ
Emerging Markets, spanning more than 125 developing countries, recorded net sales of 542.3 million USD in the second quarter of 2026, down 2% both reported and operationally due to ARV supply constraints 3. JANZ, covering Japan, Australia and New Zealand, had net sales of 296.1 million USD, down 3% reported but flat operationally 3.
Market context
The global pharmaceutical industry is highly competitive and heavily regulated, and approvals for new products are costly and hard to predict 1. Generics, particularly in the US, contribute most revenue and margin at launch, and new entrants usually reduce volumes and prices 1. Meanwhile, governments in many countries impose price cuts and tender systems that can weigh on sales and profitability, and the company guides to new product revenue of 450 to 550 million USD in 2026 13.
The industry is moving toward complex, limited-competition products where margins can be higher, and Viatris aims to focus on these as well as patent-protected innovation 1. If these launches arrive on schedule, the company could offset erosion of its mature product base, although outcomes depend on regulators and market acceptance 1.
Trends
- Growth in Greater Chinatailwind
Sales in Greater China rose sharply in the first half of 2026, suggesting regional brands could keep supporting results if the momentum holds 3.
- New product launchestailwind
Viatris has approved and launched products such as Gwyn Lo and a generic ferric carboxymaltose, and expects new product revenue of 450 to 550 million USD in 2026; if launches materialise, they could support growth 13.
- Production disruptions in Indiaheadwind
An FDA inspection of the Nashik facility produced observations, and intermittent disruptions together with an earlier fire could affect supply in the second half of 2026, with an estimated revenue impact of 100 to 150 million USD 23.
- Restructuring and divestituresmixed
The restructuring programme could deliver savings of 600 to 700 million USD, but involves charges of up to 850 million USD and execution risk, while divestitures may shrink the business 1.
Competitive position
Viatris operates in a competitive sector where generic makers compete on price, and tender systems in some countries push prices lower 1. Competitors, both generic producers and branded companies, may challenge patents or launch equivalent products, affecting volumes and margins 1.
In complex and innovative segments, Viatris competes with companies that already have patient access and regulatory experience, so timing and first-to-market launches matter 1. Rivals can influence pricing and market share, which makes differentiation through quality and supply reliability essential 1.
- Biocon Biologics
Company to which Viatris contributed its biosimilars business and in which it previously held a significant stake that it later monetised.
- Cooper Consumer Health
European OTC manufacturer and distributor that acquired Viatris's OTC business in 2024.
- Insud Pharma
Spanish multinational pharmaceutical company that acquired the women's healthcare business and part of the Upjohn portfolio.
- Harrow
North American provider of ophthalmic disease management solutions and buyer of the global rights to Tyrvaya.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report08 Oct 2026Material agreement · Other events · Financial statements and exhibits
- Quarterly report06 Aug 2026
- Current report06 Aug 2026Results of operations · Other events · Financial statements and exhibits
- Current report01 Jul 2026Material agreement · Creation of a direct financial obligation · Financial statements and exhibits
- Current report18 Jun 2026Material agreement · Creation of a direct financial obligation · Financial statements and exhibits
- Current report15 Jun 2026Other events · Financial statements and exhibits
- Current report15 May 2026Shareholder vote
- Quarterly report07 May 2026
- Current report07 May 2026Results of operations · Other events · Financial statements and exhibits
- Current report04 May 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Viatris Inc. · 26 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Viatris Inc. · 06 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Viatris Inc. · 06 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.